Abstract
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide. Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training. Endpoints included injection completeness, task durations, and user feedback via the Injection Device Experience and Acceptability–Ease of Use and Convenience Questionnaire (IDEA-ECQ; content validity supported by cognitive interviews, n = 50). All but one participant completed the injection successfully. Median training time was 3 minutes, and time to prepare and inject was 15 seconds. Participants rated the device easy/very easy to use (100%), easy/very easy to learn (98.7%), and an injection with the pen convenient (99.3%). Results were consistent across populations and unaffected by prior device experience.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
